ProCE Banner Activity

CALIBRATE: Interim Wk 28 Resistance Analysis of Long-Acting Subcutaneous Lenacapavir in Treatment-Naive Patients

Slideset Download
Limited treatment-emergent lenacapavir resistance occurred after 28 weeks of oral or subcutaneous lenacapavir plus FTC/TAF.

Released: October 05, 2021

Expiration: October 04, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Ferring Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp

ViiV Healthcare